Catheter Precision, Inc. VTAK

Company Overview

Catheter Precision, Inc. (NYSE American: VTAK) is a U.S.-based medical technology company focused on cardiac electrophysiology products used in the diagnosis and treatment of cardiac arrhythmias. The company operates within the broader cardiovascular medical device and electrophysiology industries, developing technologies intended to improve catheter navigation, arrhythmia mapping, and procedural efficiency during minimally invasive cardiac procedures. Its primary commercial focus has centered on advanced cardiac mapping and navigation systems designed for electrophysiologists treating conditions such as atrial fibrillation and other irregular heart rhythms.

The company’s principal revenue drivers include its electrophysiology technologies and related disposable or procedural products. Key products historically associated with the company include the VIVO (View Into Ventricular Onset) non-invasive cardiac mapping system and the LockeT vascular closure device. Catheter Precision evolved through acquisitions and restructuring activities involving earlier electrophysiology-focused businesses, including technology assets connected to cardiac mapping and procedural guidance. The company positions itself as a smaller specialized innovator competing in segments traditionally dominated by larger cardiovascular device manufacturers by emphasizing workflow enhancement, non-invasive mapping capabilities, and physician-focused procedural tools.

Business Operations

Catheter Precision generates revenue primarily through the commercialization of electrophysiology devices and related medical technologies used in hospital and clinical settings. Its operations are concentrated in the cardiac electrophysiology market, particularly products supporting arrhythmia diagnosis and ablation procedures. The company’s business includes the development, manufacturing oversight, regulatory management, and commercialization of its cardiac mapping and vascular access technologies. Public filings indicate that the company’s operations are principally U.S.-focused, though certain technologies may be marketed internationally through distribution relationships and strategic commercial arrangements.

The company’s core technology portfolio includes the VIVO system, which is designed to assist physicians by providing non-invasive electrocardiographic mapping data intended to localize ventricular arrhythmia origins before invasive procedures. Another major product line is LockeT, a suture retention and wound closure device intended to improve hemostasis and reduce complications following catheter-based procedures. Catheter Precision has historically relied on collaborations with physicians, clinical institutions, and third-party manufacturers to support commercialization and product deployment. Data regarding large-scale joint ventures or extensive international subsidiaries remains limited in public disclosures, and some operational details are inconclusive based on available public sources.

Strategic Position & Investments

Catheter Precision’s strategic direction has focused on expanding adoption of its electrophysiology technologies while increasing procedural integration within cardiac care settings. Company disclosures and investor materials have emphasized commercial expansion efforts for VIVO and LockeT, including physician education, hospital penetration strategies, and broader electrophysiology lab utilization. The company has also highlighted the importance of obtaining and maintaining regulatory clearances, reimbursement positioning, and clinical validation studies to support long-term growth.

The company’s historical growth strategy has included acquisitions and integration of electrophysiology-related assets and technologies. Public filings reference prior transactions involving cardiac mapping businesses and intellectual property intended to strengthen its position in non-invasive arrhythmia localization. Catheter Precision operates in a competitive market that includes larger multinational medical device firms, and its strategy appears centered on niche innovation and differentiated workflow tools rather than broad platform dominance. The company remains involved in emerging areas of cardiac mapping and minimally invasive electrophysiology technologies, though detailed disclosures regarding future pipeline investments or large-scale capital deployment are limited in publicly available information.

Geographic Footprint

Catheter Precision is headquartered in the United States, with principal operations associated with the U.S. electrophysiology and cardiovascular device market. The company’s commercial activities primarily target hospitals, electrophysiology laboratories, and cardiac specialists within North America. Public disclosures indicate that the company seeks broader market reach through distributors and commercial partnerships, though its operational footprint remains significantly smaller than major global cardiovascular device manufacturers.

The company’s technologies have potential applicability across international electrophysiology markets, including regions in Europe and other medically developed healthcare systems where arrhythmia treatment volumes continue to increase. However, publicly verified information regarding extensive foreign subsidiaries, manufacturing hubs, or direct international operational infrastructure remains limited. Data regarding the scale of international revenue contribution is inconclusive based on available public sources.

Leadership & Governance

Catheter Precision is led by an executive team with experience in medical devices, commercialization, and cardiovascular technologies. Company governance and strategic oversight are guided through public-company reporting obligations, including disclosures contained in SEC filings and annual reports. Leadership communications have emphasized innovation in electrophysiology workflow improvement, physician usability, and expansion of commercial adoption for the company’s core technologies.

Key executives and leadership figures publicly associated with the company include:

• David Jenkins – Chief Executive Officer
• Steve Gorlin – Executive Chairman
• Todd Usen – Director
• Stuart Long – Chief Financial Officer

The company’s leadership strategy has focused on advancing commercialization while maintaining a targeted portfolio within electrophysiology and catheter-based procedural technologies. Public statements and investor materials consistently frame the company’s vision around improving procedural precision, reducing complexity in arrhythmia treatment, and expanding clinical adoption of differentiated mapping technologies.